Advertisement
Product › Details
MAb, human, fully
Next higher product group | antibody | |
Record changed: 2023-07-10 |
Advertisement
More documents for MAb, human, fully
- [1] Sanofi S.A.. (1/11/21). "Press Release: Sanofi to Acquire Kymab, Adding KY1005 to Its Pipeline, a Human Monoclonal Antibody Targeting Key Immune System Regulator OX40L". Paris & Cambridge....
- [2] Yumab GmbH. (5/7/20). "Press Release: Yumab Identifies Promising Candidate for Covid-19 Antibody Therapy". Braunschweig....
- [3] BioNTech SE. (5/8/19). "Press Release: BioNTech Acquires MabVax Therapeutics’ Antibody Assets to Expand Portfolio". Mainz....
- [4] MorphoSys AG. (11/23/17). "Press Release: MorphoSys Announces that Its Licensee Janssen Has Received Approval for Tremfya (Guselkumab) in Europe for the Treatment of Moderate-to-Severe Plaque Psoriasis". Planegg....
- [5] Novimmune S.A.. (7/18/17). "Press Release: Novimmune and Shire Sign License Agreement Deepening Bispecific Antibody Research Collaboration". Geneva....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top